483 Zhejiang Kangle Pharmaceutical (Binhai Plant) Mar 2019

483 Zhejiang Kangle Pharmaceutical (Binhai Plant) Mar 2019

Christopher Middendorf FDA$119.00 - Available Now

FDA investigators audited the Zhejiang Kangle Pharmaceutical (Binhai Plant) - Wenzhou, China facility and issued inspectional observations (via FDA 483) on 22 Mar 2019.

Product details

  • Category: Human Drugs
  • Inspection end: 22 Mar 2019
  • Location: Wenzhou, China
  • FEI: 3010728912
Add To Cart